(AOF) – Merck and Moderna announce the launch of INTerpath-002, a phase 3 study evaluating V940 (mRNA-4157) in combination with Keytruda (pembrolizumab), Merck’s lead product, for the adjuvant treatment of patients with certain types of non-small cell lung cancer resected. The launch of the second clinical trial of the INTerpath program is being touted as a sign of a rapid expansion of research into additional tumor types for individualized neoantigen therapy.
“As lung cancer is the leading cause of cancer deaths worldwide, continued scientific advances are needed to help combat this disease at early stages, when patients have the best chance of better outcomes,” he said. said Dr. Marjorie Green, vice president and head of late-stage oncology at Merck Research Laboratories. “By combining Keytruda with V940 (mRNA-4157), a promising new modality, we are exploring innovative new approaches.”